Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled time : 10:00 save search
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
Published: 2023-11-06 (Crawled : 10:00) - prnewswire.com
KOD | News | $3.33 -2.63% -2.7% 21
|
Health Technology
|
| O: -11.02%
H: 12.38%
C: -2.86%
glow positive program results study submission diabetic
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9232 -3.82% -4.33% 43K
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Published: 2023-09-26 (Crawled : 10:00) - globenewswire.com
ROIV | $10.94 3.21% 3.06% 0
|
Manufacturing
|
| O: 15.57%
H: 8.73%
C: 5.17%
IMVT S | $28.61 -0.45% -0.31% 32
|
Health Technology
|
| O: 59.22%
H: 29.2%
C: 23.75%
imvt-1402 positive results
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Published: 2023-09-26 (Crawled : 10:00) - globenewswire.com
IMVT S | $28.61 -0.45% -0.31% 32
|
Health Technology
|
| O: 59.22%
H: 29.2%
C: 23.75%
imvt-1402 positive results
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
Published: 2023-09-14 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9232 -3.82% -4.33% 43K
|
n/a
|
| O: -18.99%
H: 10.34%
C: -7.59%
positive update collaboration
Digihost Reports Positive Adjusted EBITDA for Q2 2023
Published: 2023-08-15 (Crawled : 10:00) - globenewswire.com
DGHI | $1.28 -5.19% -5.47% 160K
|
n/a
|
| O: 3.66%
H: 0.59%
C: -8.24%
positive
India Data Center Market Investment Opportunities, 2023-2028: Microsoft and AWS are Involved in Self-built Data Centers, Creating a Positive Outlook for the Long-term
Published: 2023-08-14 (Crawled : 10:00) - prnewswire.com
ACM | $93.88 1.57% -0.09% 350K
|
Industrial Services
|
| O: 1.11%
H: 1.85%
C: 1.77%
positive india market
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Published: 2023-07-04 (Crawled : 10:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
| Email alert
Add to watchlist
PTGX S | $26.85 0.9% 0.78% 5
|
Health Technology
| Email alert
Add to watchlist
jnj-2113 psoriasis positive il-23 topline therapeutics results
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
Published: 2023-07-03 (Crawled : 10:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
zp8396 pharma positive trial results
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Published: 2023-06-29 (Crawled : 10:00) - globenewswire.com
BTAI | News | $2.97 4.21% 3.88% 0
|
Health Technology
|
| O: -51.1%
H: 9.49%
C: -26.04%
bxcl501 alzheimer’s positive treatment topline trial therapeutics results
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
Digihost Reports Positive Adjusted EBITA for Q1 2023 and Provides Operational Update
Published: 2023-05-16 (Crawled : 10:00) - globenewswire.com
DGHI | $1.28 -5.19% -5.47% 160K
|
n/a
|
| O: 0.0%
H: 0.0%
C: -1.97%
positive update
HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
Published: 2023-04-11 (Crawled : 10:00) - prnewswire.com
IMAB | $1.8 0.55% 210
|
Health Technology
|
| O: 0.0%
H: 4.2%
C: 3.08%
nephropathy positive treatment phase 2
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
Published: 2023-03-09 (Crawled : 10:00) - biospace.com/
BPTS | $9.82 -15.37% -24.77% 24
|
Manufacturing
|
| O: 40.0%
H: 0.0%
C: -15.64%
lung conference positive results study phase 2
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
Published: 2022-12-08 (Crawled : 10:00) - biospace.com/
ADXN | $18.74 -2.8% -10.32% 800
|
Health Technology
|
| O: 2.48%
H: 5.61%
C: 0.02%
research collaboration positive
Photocure ASA: Results for the third quarter of 2022 Photocure ASA reported Hexvix®/Cysview® revenues of NOK 96.9 million in the third quarter of 2022, up 12% compared to Q3 2021, and positive EBITDA o...
Published: 2022-11-02 (Crawled : 10:00) - biospace.com/
VRNA | $15.59 -0.83% -0.77% 360K
|
Health Technology
|
| O: 1.21%
H: 1.87%
C: -2.88%
hexvix positive
Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis
Published: 2022-10-11 (Crawled : 10:00) - prnewswire.com
NVO | News | $128.64 2.7% -1.37% 60K
|
Health Technology
|
| O: -0.25%
H: 1.95%
C: 0.77%
pharma seeds positive
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
Published: 2022-07-05 (Crawled : 10:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
ant-01 fda drug positive major depressive disorder
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in inno...
Published: 2022-06-22 (Crawled : 10:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 2.73%
H: 6.19%
C: 1.77%
trial positive results zygel topline
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
RILY | $21.72 0.84% 32.09% 1.9M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
PEB 4 | $15.45 2.45% 10.46% 130
|
Finance
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.